Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
NCT00138723
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
INDUSTRY
Sponsor class
Conditions
Overactive Bladder
Interventions
DRUG:
SPM 907
Sponsor
Pfizer